Thermo Fisher Scientific TMO has introduced the Invitrogen EVOS S1000 Spatial Imaging System. This advanced system addresses the limitations of current fluorescent microscopy technologies by enabling researchers to generate a multiplexed high-quality image for multiple samples within several hours, lowering the barrier to entry into spatial tissue proteomics.

Launched commercially in the United States and Europe, Thermo Fisher’s new system provides researchers with the tools to help advance the understanding of complex biological systems and develop new treatments for various diseases.

Likely Trend of TMO Stock Following the News

After the announcement yesterday, TMO shares fell by 1.3%, closing at $538. On a promising note, the company continues to see the impact of its past innovations while bringing several high-impact new products. We expect that the latest development will positively boost the market sentiment toward TMO stock.

Presently, Thermo Fisher boasts a market capitalization of $208.55 billion. The Zacks Consensus Estimate forecasts a 2.4% increase in the company’s earnings and 2.4% growth in revenues, both on a year-over-year basis. It surpassed earnings estimates in each of the trailing four quarters, delivering an earnings surprise of 4.21%.  

Importance of TMO’s New Spatial Imaging System

The EVOS S1000, from Thermo Fisher Scientific’s innovative line of cell imaging microscopes and systems, utilizes advanced and patented spectral technology to capture images of up to 9 different targets simultaneously. This helps reduce the need for multiple rounds of imaging and preserves tissue integrity. Understanding tissue structure and function is essential for developing new treatments for solid tumors and neurodegenerative diseases.

Image Source: Zacks Investment Research

Per a Thermo Fisher representative, the EVOS S1000 delivers a detailed snapshot of tissue microenvironments and architecture in their native state, helping researchers accelerate their experiments, achieve more with their tissue samples and drive advancements in critical research areas. The system’s compatibility with a wide range of reagents and antibodies enables seamless integration into existing laboratory setups, helping meet the growing demand for multiplex imaging.

Industry Prospects Favoring Thermo Fisher

Per a Research report, the Spatial Proteomics market was valued at $92.4 million in 2024 and is expected to witness a compound annual rate of 12.7% through 2030. Key factors fueling the market’s growth include the integration of high-resolution imaging techniques, mass spectrometry advancements and artificial intelligence in data analysis. As pharmaceutical and biotechnology companies advance precision medicine, spatial proteomics is essential for identifying biomarkers and therapeutic targets.

More Updates From Thermo Fisher

Earlier this month, Thermo Fisher announced the launch of the international CorEvitas Adolescent Alopecia Areata (“AA”) Registry, addressing a critical unmet need for real-world, adolescent-specific evidence and data related to this autoimmune disease, which leads to patchy or complete hair loss on the scalp and other areas of the body. The data collected will help research better understand the burden of disease for AA patients, as well as the real-world effectiveness and safety of newly approved treatments.

TMO Stock Price Performance

In the past year, TMO shares have fallen 1.9% against the industry’s rise of 5.9%.

TMO’s Zacks Rank and Key Picks

Thermo Fisher currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader medical space are Boston Scientific BSX, Penumbra PEN and Phibro Animal Health PAHC. While Boston Scientific sports a Zacks Rank #1 (Strong Buy) at present, Penumbra and Phibro Animal Health each carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Estimates for Boston Scientific’s 2025 earnings per share have jumped 2.9% to $2.85 in the past 30 days. Shares of the company have surged 60.4% in the past year compared with the industry’s growth of 15.9%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.25%. In the last reported quarter, it delivered an earnings surprise of 7.69%.

Penumbra shares have dipped 0.5% in the past year. Estimates for the company’s 2024 earnings per share have remained constant at $2.81 in the past 30 days. PEN’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 10.54%. In the last reported quarter, it posted an earnings surprise of 23.19%.

Estimates for Phibro Animal Health’s fiscal 2025 earnings per share have increased 5.6% to $1.71 in the past 30 days. Shares of the company have surged 105.9% in the past year compared with the industry’s 15.9% rise. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.06%. In the last reported quarter, it delivered an earnings surprise of 28.57%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Boston Scientific Corporation (BSX) : Free Stock Analysis Report

Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report

Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report

Penumbra, Inc. (PEN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research